Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET gene abnormalities
Brief description of study
The purpose of the study is to determine the safety and tolerability of TAS0953/HM06. We want to know what is the best study drug dose. TAS0953/HM06 is a potent and highly selective inhibitor of the phosphorylation of REarranged during Transfection (RET) tyrosine kinase. The study drug TAS0953/HM06 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-00854
ClinicalTrials.gov Identifier: NCT04683250
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
